ArticleThe Prostate2019

TGF-β receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer.

Channing Paller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.